SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

Home・Aktien・Vetoquinol SA

Vetoquinol SA

Geschlossen

BrancheGesundheitswesen

70.59 -1.69

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

69.7

Max

71.8

Schlüsselkennzahlen
By Trading Economics
Einkommen	7.2M 32M
Verkäufe	10M 268M
KGV Branchendurchschnitt	14.777 51.415
Dividendenrendite	1.25
Gewinnspanne	12.043
Angestellte	2,497
EBITDA	252M 301M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+50.68% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	1.25% 2.34%

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-86M 849M
Vorheriger Eröffnungskurs	72.28
Vorheriger Schlusskurs	70.59

Nachrichtenstimmung

By Acuity

50%

150 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

72.6 / 75.1 Unterstützung & Widerstand

Vetoquinol SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2026, 22:50 UTC

Ergebnisse

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. Mai 2026, 22:49 UTC

Ergebnisse

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. Mai 2026, 22:32 UTC

Ergebnisse

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. Mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. Mai 2026, 22:57 UTC

Market Talk

Ergebnisse

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. Mai 2026, 22:26 UTC

Ergebnisse

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure Interim Dividend A$0.50/Security

12. Mai 2026, 22:24 UTC

Ergebnisse

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. Mai 2026, 22:19 UTC

Ergebnisse

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. Mai 2026, 22:13 UTC

Ergebnisse

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. Mai 2026, 22:11 UTC

Ergebnisse

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. Mai 2026, 22:11 UTC

Ergebnisse

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. Mai 2026, 22:10 UTC

Ergebnisse

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. Mai 2026, 22:08 UTC

Ergebnisse

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. Mai 2026, 22:07 UTC

Ergebnisse

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. Mai 2026, 22:05 UTC

Ergebnisse

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer-Vergleich

Kursveränderung

Vetoquinol SA Prognose

Kursziel

By TipRanks

50.68% Vorteil

12-Monats-Prognose

Durchschnitt 110 EUR 50.68%

Hoch 110 EUR

Tief 110 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vetoquinol SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vetoquinol SA – Dist abgegeben haben.

Technischer Score

By Trading Central

72.6 / 75.1Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Stimmung

By Acuity

150 / 346 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.